About This Deal

AbbVie acquired Syndesi Therapeutics SA for $130 million upfront, a transaction completed in February 2022, structured as cash upfront plus contingent milestones.

Syndesi Therapeutics SA operates in Neuroscience, is based in Belgium. AbbVie acquired Syndesi and its portfolio of novel modulators of the synaptic vesicle protein 2A, including lead molecule ABBV-552 (formerly SDI-118). ABBV-552 is a small molecule evaluated to target nerve terminals and enhance synaptic efficiency. AbbVie made a $130 million upfront payment, recorded as acquired IPR&D, and accounted for it as an asset acquisition.

Adds an early-stage neuroscience asset targeting synaptic function to AbbVie's pipeline.

Deal Terms

Acquirer
AbbVie
Target
Syndesi Therapeutics SA
Value
$130 million upfront
Date
February 2022
Type
Asset acquisition
Status
Ready

Transaction Details

Target HQ
Belgium
Segment
Neuroscience
Structure
Cash upfront plus contingent milestones
Closed
February 1, 2022

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.